A study of a drug called NEO212 for brain tumors and cancer that has spread to the brain
Original title: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so it is still being checked for safety.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called NEO212 in people whose brain tumor has grown, and in people whose cancer has spread to the brain.
Who this trial is for. This trial is for adults with an astrocytoma (IDH gene change: A small change in a tumor's IDH gene. Tumors with this change often grow more slowly and may respond to different treatments. Your pathology report says whether your tumor has it. See the glossary) or a glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary (IDH-wildtype) that scans show has grown, and for people with a solid tumor cancer that has spread to the brain and is not under control. It tests a drug called NEO212, given by itself for the brain tumor group, and given with standard care for the group whose cancer spread to the brain.
Where it stands. This trial has not reported results. It is looking at how safe the drug is, how the body handles it, and whether it helps. The answers are not in yet. The study is set up to run in stages, starting small and then growing.
What this means, and what it doesn't
What it could mean: This is one of the places a new drug is being tested for these tumors. If your situation sounds like the people described here, you can ask your care team about it. They can tell you if it makes sense for you and help you look into it.
What it doesn't mean: This does not mean NEO212 works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that you will be helped, and the drug may not help at all. This is not a promise of a cure. It is also not a promise that you can join. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.